Press Releases

ClariMed, Inc., today announced the launch of the first MedTech services partner to take an integrated, human-centric approach to medical product development.  The Company also announced today the acquisition of San Jose-based UserWise, LLC, and the appointment of Kelley Kendle as Chief Executive Officer and Chair of the Board of Directors. The Company was formed in partnership with NaviMed Capital, a private investment firm focused exclusively on the healthcare industry. ClariMed

Kite, a Gilead Company  and Arcellx, Inc. today announced the closing of the companies’ previously announced global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, safe and broadly accessible therapies. Currently being investigate

InDex Pharmaceuticals Holding AB  today announced an update in the timing of the dose selection in the ongoing phase III study CONCLUDE with the drug candidate cobitolimod. The outcome of the dose selection is expected to be available Q4 2023. At that point in time InDex will have finalised the assessments of consequences on the overall development timeline including topline results in CONCLUDE. "Patient recruitment for the global phase III study CONCLUDE is under way. How

ExeGi Pharma LLC, a leader in the development of live biotherapeutic drugs and probiotics, announced today that the FDA has cleared its Investigational New Drug  application for its biologic drug candidate, EXE-346. This clearance allows the company to initiate a clinical trial for patients with an ileal pouch-anal anastomosis who experience excessive stool frequency. "Excessive stool frequency is a significant challenge for many patients with a J-Pouch, and we are pleased to

Mitsubishi Tanabe Pharma America, Inc. today announced that nearly 4,000 people with amyotrophic lateral sclerosis (ALS) have received RADICAVA ORS since the therapy became available in the U.S. in June 2022, and 79% of patients who started treatment with RADICAVA ORS or intravenous RADICAVA between June 1, 2022 and September 30, 2022 have continued treatment for three months or more through December.1,2 To date, more than 600 U.S. healthcare providers (HCPs) have prescribed RADICAVA ORS sinc

Innate Pharma SA announced today the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to the previously announced expansion of its collaboration with Sanofi. The licensing agreement is now effective. As announced on December 19, 2022, Sanofi is licensing a Natural Killer (NK) cell engager program targeting B7H3 from Innate’s ANKET® (Antibody-based NK Cell Engager Therapeutics) platform. Sanofi will also have the o

Aculys Pharma, Inc. a company focused on the development and commercialization of new innovative drugs in the fields of neurology and psychiatry, and Four H, Inc.a Japan- based company specializing in health technology, announced an exploratory research collaboration using wearable devices to help patients with narcolepsy and excessive daytime sleepiness associated with obstructive sleep apnea syndrome. In its quest to establish a new pharmaceutical model, Aculys is promoting DX (digit

Astellas Pharma Inc. today announced that Astellas and Sandoz AG  have entered into an Asset Purchase Agreement, under which Astellas will transfer the world wide product rights for antifungal agent MYCAMINE. Once the transaction closes, Sandoz will acquire the rights to sell the product globally. Astellas will work closely with Sandoz to enable a smooth transition. 1.Purpose of Asset Purchase Agreement The agreement is a part of Astellas

Sun Pharmaceutical Industries Limited   and Concert Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement pursuant to which Sun Pharma will acquire all of the outstanding shares of Concert by way of a tender offer for an initial cash payment of 8.00 dollars per common share, or $576 million in net worth. Concert shareholders will also receive a non-negotiable contingent value right (CVR) entitling them to receive cash up to an additional $3.50 per

Australian biotech company Ferronova announced today it has secured a further A$11 million to progress the company's nanoparticle platform to assist surgeons to more accurately locate and remove malignant cells during treatment of gastrointestinal and brain tumors. Irish company Renew Pharmaceuticals Limited (Renew) led an A$8 million capital raise, with a further A$3 million secured via an Australian Government Co-operative Research Centers Project (CRC-P) grant.* Existing Ferr